Fresenius Stock Surges After Raising Full-Year Profit Forecast

Shares of Fresenius SE (FREG) surged 5.6% to €46.85 on Tuesday after the German healthcare group raised its full-year earnings forecast, citing an "excellent Q2 performance" that it said demonstrates a structural improvement in its earnings power.

Upgraded Outlook and Q2 Performance

In an ad-hoc announcement accompanying its second-quarter results, Fresenius lifted its guidance for full-year 2026 constant-currency core earnings per share (EPS) growth. The company now projects growth in a range of 10% to 15%, a significant increase from the previous target of 5% to 10%.

The revised forecast was supported by a strong set of quarterly results. Key figures for the second quarter include:

• Organic revenue growth of 6% to €5,864 million.
• Group EBIT before special items rose 10% in constant currency to €719 million.
• The EBIT margin expanded by 60 basis points to 12.3%.
• Adjusted EPS grew 14% in constant currency to €0.83.

Ad

Kabi Division Shines

A key driver of the strong results was the company's Fresenius Kabi division, particularly its "Growth Vectors" business. According to the release, the segment's EBIT surged 42% in constant currency, with its margin reaching 17.9%. This brought the division's profitability into its recently upgraded structural margin band for the first time.

Market Context

The stock's rally was supported by a broadly positive market environment, with Germany's DAX index trading near record highs. The performance stood in contrast to its peer, Fresenius Medical Care, which had reported weaker U.S. treatment volumes a day earlier, highlighting Fresenius SE’s operational outperformance. The combination of the earnings beat, upgraded guidance, and a supportive market backdrop pushed the stock toward the upper end of its 52-week range of €35.11–€52.96.